| Business Summary | | Orthovita
Inc.
is
a
biomaterials
company
that
has
proprietary
techniques
for
the
development
of
novel
products
for
use
in
orthopaedics.
The
Company's
focus
is
on
developing
products
for
use
in
surgical
procedures
in
spine
and
osteoporotic
fractures.
Orthovita
is
also
addressing
a
broad
range
of
clinical
needs
in
the
trauma
market.
The
Company's
efforts
to-date
have
resulted
in
the
development
of
three
products:
VITOSS
Synthetic
Cancellous
Bone
Void
Filler,
CORTOSS
Cortical
Bone
Void
Filler,
and
RHAKOSS
Synthetic
Bone
Implants. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Orthovita
is
a
developer
of
biomaterials
and
orthobiologics
focused
on
synthetic
bone
substitute
products
for
orthopaedic
applications
primarily
in
spine.
The
Company
is
also
developing
complementary
bone
products.
For
the
six
months
ended
6/30/01,
revenues
totalled
$1.2
million,
up
from
$533
thousand.
Net
loss
totaled
$6.9
million,
up
from
$3.3
million.
Revenues
reflect
initital
product
sales
of
VITOSS.
Loss
reflects
a
decrease
in
the
gain
on
sale
of
Biogran. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| David Joseph, 58 Chairman. | $310K | Bruce Peacock, 49 CEO,
Pres, Chief Operating Officer, Director | 560K | Joseph Paiva VP,
CFO | 220K | Erik Erbe, Ph.D. VP-R&D | 215K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|